Fibromyalgia Therapeutics Market Size, Share, And Growth Report 2032

Fibromyalgia Therapeutics Market

Fibromyalgia Therapeutics Market by Drug Class (Antidepressants (Duloxetine, Milnacipran, and Other Drugs), Antiepileptic’s (Gabapentin, Pregabalin, and Other Drugs), Muscle Relaxants, Analgesics, and Other Drugs), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region - Global And Regional Industry Overview, market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024-2032-

Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-4996 Published Date: Aug-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 2.74 Billion USD 4.00 Billion 4.3% 2023

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
    • 2.2. Fibromyalgia Therapeutics Market: Snapshot
  • Chapter 3. Fibromyalgia Therapeutics Market - Industry Analysis
    • 3.1. Fibromyalgia Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Drug Class
      • 3.6.2. Market attractiveness analysis By Distribution Channel
      • 3.6.3. Market attractiveness analysis by Region
  • Chapter 4. Fibromyalgia Therapeutics Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Fibromyalgia Therapeutics Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Drug Class launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Fibromyalgia Therapeutics Market - By Drug Class Analysis
    • 5.1. Global Fibromyalgia Therapeutics Market overview: By Drug Class
      • 5.1.1. Global Fibromyalgia Therapeutics Marketshare, By Drug Class,2018 and 2025
    • 5.2. Antidepressants (Duloxetine, Milnacipran, and Other Drugs)
      • 5.2.1. Global Fibromyalgia Therapeutics Market by Antidepressants (Duloxetine, Milnacipran, and Other Drugs), 2016-2025 (USD Million)
    • 5.3. Antiepileptic's (Gabapentin, Pregabalin, and Other Drugs)
      • 5.3.1. Global Fibromyalgia Therapeutics Market by Antiepileptic's (Gabapentin, Pregabalin, and Other Drugs), 2016-2025 (USD Million)
    • 5.4. Muscle Relaxants
      • 5.4.1. Global Fibromyalgia Therapeutics Market by Muscle Relaxants, 2016-2025 (USD Million)
    • 5.5. Analgesics
      • 5.5.1. Global Fibromyalgia Therapeutics Market by Analgesics, 2016-2025 (USD Million)
    • 5.6. Others
      • 5.6.1. Global Fibromyalgia Therapeutics Marketby others, 2016-2025 (USD Million)
  • Chapter 6. Global Fibromyalgia Therapeutics Market -Distribution Channel Analysis
    • 6.1. Global Fibromyalgia Therapeutics Market overview: By Distribution Channel
      • 6.1.1. Global Fibromyalgia Therapeutics Market share, By Distribution Channel, 2018 and 2025
    • 6.2. Hospital Pharmacy
      • 6.2.1. Global Fibromyalgia Therapeutics Market By Hospital Pharmacy, 2016-2025 (USD Million)
    • 6.3. Retail Pharmacy
      • 6.3.1. Global Fibromyalgia Therapeutics MarketBy Retail Pharmacy, 2016-2025 (USD Million)
    • 6.4. Online Pharmacy
      • 6.4.1. Global Fibromyalgia Therapeutics Market By Online Pharmacy, 2016-2025 (USD Million)
  • Chapter 7. Global Fibromyalgia Therapeutics Market - Regional Analysis
    • 7.1. Global Fibromyalgia Therapeutics Market overview: by Region
      • 7.1.1. Global Fibromyalgia Therapeutics Marketshare, by Region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.2.2. North America Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.2.3. North America Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S.Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.2.4.2. The U.S.Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.2.5.2. Rest of North America Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.3.2. Europe Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.3.3. Europe Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.4. UK
        • 7.3.4.1. U.K.Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.4.2. U.K.Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.5.2. France Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.6. Germany
        • 7.3.6.1. Germany Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.6.2. Germany Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of EuropeFibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.7.2. Rest of EuropeFibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.4.2. Asia Pacific Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
      • 7.4.3. Asia Pacific Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.4. China
        • 7.4.4.1. China Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.4.2. China Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.5. Japan
        • 7.4.5.1. Japan Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.5.2. Japan Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.6. India
        • 7.4.6.1. India Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.6.2. India Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.5.2. Latin America Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
      • 7.5.3. Latin America Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.5.4.2. Brazil Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.5.5. Rest of LatinAmerica
        • 7.5.5.1. Rest of LatinAmerica Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.5.5.2. Rest of LatinAmerica Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.6.2. The Middle East and Africa Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.6.3. The Middle East and Africa Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1. Pfizer, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Drug Class Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Eli Lilly and Company
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Drug Class Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Novartis AG
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Drug Class Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Sun Pharmaceutical Industries Ltd.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Drug Class Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Allergan Plc
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Drug Class Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Aptinyx, Inc
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Drug Class Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Astellas Pharma, Inc.
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Drug Class Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Innovative Med Concepts, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Drug Class Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Prismic Pharmaceuticals, Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Drug Class Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. Intec Pharma Ltd.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Drug Class Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development

Methodology

FrequentlyAsked Questions

Fibromyalgia therapeutics encompass a range of treatments aimed at managing the symptoms of fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and tenderness in the muscles and soft tissues.

According to study, the Fibromyalgia Therapeutics Market size was worth around USD 2.74 billion in 2023 and is predicted to grow to around USD 4.00 billion by 2032.

The CAGR value of Fibromyalgia Therapeutics Market is expected to be around 4.3% during 2024-2032.

North America has been leading the Fibromyalgia Therapeutics Market and is anticipated to continue on the dominant position in the years to come.

The Fibromyalgia Therapeutics Market is led by players like Pfizer Inc., Eli Lilly, and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Allergan Plc, Aptinyx Inc., Astellas Pharma Inc., Innovative Med Concepts Inc., Prismic Pharmaceuticals Inc., Intec Pharma Ltd., Sanofi, and Bayer AG.

  • zion payment modes

List of Contents

Market SizeOverviewSegmentationReport ScopeRegional AnalysisCompetitive PlayersThe Global Market is segmented as follows:

HappyClients